Literature DB >> 16945643

Botulinum A toxin urethral sphincter injection in children with nonneurogenic neurogenic bladder.

I Mokhless1, S Gaafar, K Fouda, M Shafik, A Assem.   

Abstract

PURPOSE: We evaluated botulinum-A toxin (Botox) injection into the urethral urinary sphincter in children with nonneurogenic neurogenic bladder to decrease urethral resistance and improve voiding. In these patients alpha-blocker medications had failed and injection was an alternative to unavailable biofeedback.
MATERIALS AND METHODS: Prospective treatment was performed in 10 children 6 to 17 years old (mean age 8) with nonneurogenic neurogenic bladder using botulinum-A toxin (Botox). Preoperatively all children were evaluated by ultrasound, voiding cystourethrography, excretory urography, magnetic resonance imaging and urodynamic studies, including pressure flow, electromyography and uroflowmetry. One patient had unilateral G3 reflux and 4 had bilateral G1 to G3 hydronephrosis. Using a rigid pediatric endoscope and a 4Fr injection needle 50 to 100 IU botulinum-A toxin were injected into the external sphincter at the 3, 6 and 9 o'clock positions. Followup was 6 to 15 months. Repeat injections every month were given according to the response with a maximum of 3 injections.
RESULTS: Immediately after botulinum-A toxin injection all except 1 patient were able to void without catheterization. No acute complications occurred. Four patients with bilateral hydronephrosis and the patient with the refluxing unit showed regression. Postoperatively post-void residual urine decreased by 89%, detrusor leak point pressure decreased significantly by a mean +/- SD of 66 +/- 18 vs 37 +/- 4 cm H(2)O and uroflowmetry showed a marked increase in maximum urine flow of 2 +/- 2 vs 17.8 +/- 8 ml per second. Three injections were needed in 1 patient to attain the desired response.
CONCLUSIONS: Urethral sphincter botulinum-A toxin injection could be considered a reliable treatment modality in children with nonneurogenic neurogenic bladder after the failure of conservative therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16945643     DOI: 10.1016/j.juro.2006.03.119

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  17 in total

Review 1.  Updates of underactive bladder: a review of the recent literature.

Authors:  Xing Li; Limin Liao
Journal:  Int Urol Nephrol       Date:  2016-03-01       Impact factor: 2.370

Review 2.  Dysfunctional Voiders-Medication Versus Urotherapy?

Authors:  Angela M Arlen
Journal:  Curr Urol Rep       Date:  2017-02       Impact factor: 3.092

Review 3.  Botulinum toxin A's expanding role in the management of pediatric lower urinary tract dysfunction.

Authors:  Tarek Hassouna; Joseph M Gleason; Armando J Lorenzo
Journal:  Curr Urol Rep       Date:  2014-08       Impact factor: 3.092

Review 4.  Botulinum toxin in paediatric urology: a systematic literature review.

Authors:  Ranan DasGupta; Feilim Liam Murphy
Journal:  Pediatr Surg Int       Date:  2008-10-25       Impact factor: 1.827

5.  Quantitative evaluation of electrodes for external urethral sphincter electromyography during bladder-to-urethral guarding reflex.

Authors:  James E Steward; Jessica D Clemons; Paul J Zaszczurynski; Robert S Butler; Margot S Damaser; Hai-Hong Jiang
Journal:  World J Urol       Date:  2009-08-13       Impact factor: 4.226

Review 6.  Current and potential urological applications of botulinum toxin A.

Authors:  Yuan-Hong Jiang; Chun-Hou Liao; Hann-Chorng Kuo
Journal:  Nat Rev Urol       Date:  2015-08-11       Impact factor: 14.432

Review 7.  The use of botulinum neurotoxin type A (BoNTA) in urology.

Authors:  A Apostolidis; C J Fowler
Journal:  J Neural Transm (Vienna)       Date:  2008-03-06       Impact factor: 3.575

Review 8.  Current pharmacological and surgical treatment of underactive bladder.

Authors:  Dae Kyung Kim
Journal:  Investig Clin Urol       Date:  2017-11-17

9.  Treatment strategy according to findings on pressure-flow study for women with decreased urinary flow rate.

Authors:  Yoshinori Tanaka; Naoya Masumori; Taiji Tsukamoto; Seiji Furuya; Ryoji Furuya; Hiroshi Ogura
Journal:  Adv Urol       Date:  2009-10-13

10.  OnabotulinumtoxinA Urethral Sphincter Injection as Treatment for Non-neurogenic Voiding Dysfunction - A Randomized, Double-Blind, Placebo-Controlled Study.

Authors:  Yuan-Hong Jiang; Chung-Cheng Wang; Hann-Chorng Kuo
Journal:  Sci Rep       Date:  2016-12-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.